Bio-Intelligence: Biobanks as the New Battleground for Technological Rivalry and Systemic Risks Between China and the West

The geopolitical landscape of 2026 is marked by the definitive transformation of genomic data and storage infrastructure—biobanks—from scientific resources into pillars of national security. China has led this radical shift with regulations that took effect on January 1, 2025, which supplement the PIPL (Personal Information Protection Law) and the Data Security Law.

In this context, large-scale genomic data and biological samples stored in biobanks are classified as "Core Data." The Ministry of Science and Technology (MOST) now exercises total control: any transfer of samples or sequences abroad (HGR Restrictions) requires authorization, which is often denied on grounds of national interest. This structure has created a strategic imbalance: while Beijing draws on open Western databases, China’s biological “vaults” remain tightly sealed to exclusively fuel the domestic industrial ecosystem.

GettyImages

Xi Jinping’s Doctrine and the Self-Sufficiency of the 15th Five-Year Plan

The future of Xi Jinping’s policy is shaped by an obsession with internal stability and technological self-sufficiency. With the conclusion of the 14th Five-Year Plan in 2025, China has achieved leadership in sequencing, but the real leap forward is underway with the 15th Five-Year Plan (2026–2030). The goal is absolute independence in critical sectors: sequencing chips, AI applied to biology, and advanced seeds.

Xi has eliminated collegiality, centralizing all decision-making under his authority and using bio-digital technologies to monitor systemic, health, and social risks. The timeline is clear:

• 2035. Become a world leader in the bioeconomy and complete the industrial modernization of the defense sector.

• 2049 (Centenary). Establish itself as a dominant global superpower in every high-tech sector.

The Infrastructure of Power: Biobanks and National Samples

The implementation of this strategy relies on physical infrastructure of enormous scale. The China National GeneBank (CNGB) in Shenzhen, managed by the giant BGI Group, is the beating heart of this network. It is not merely a repository, but a hub that integrates biological samples with massive supercomputing to transform organic material into digital assets analyzable by AI.

Alongside BGI, companies such as MGI Tech (hardware) and WuXi AppTec (research services) form a vertical ecosystem. The United States, through the BIOSECURE Act, blacklisted these entities in 2026, fearing that Chinese biobanks would be used for the surveillance of minorities or to develop dual-use biotech technologies. MOST acts as the ultimate guardian: every sample that enters these facilities becomes strategic property of the Chinese state.

Critical Risks to Western National Security

Western governments today face threats that go beyond traditional espionage. The primary concern is the loss of health sovereignty: if China gains control over global genomic data and biomanufacturing capabilities, the West could find itself in a position of strategic dependence when it comes to the development of vaccines, gene therapies, and cancer drugs.

There is also the risk of bio-digital surveillance: the use of genetic data to identify or monitor individuals on a global scale. The convergence of AI and synthetic biology now makes it possible to design biological agents with surgical precision (Dual-Use 2.0). Governments fear that such capabilities could be diverted toward the optimization of pathogens or the control of public health through the monitoring of specific genetic vulnerabilities across entire populations.

Vulnerabilities of Private Companies: Erosion of Confidentiality and "Model Laundering"

For companies in the life sciences sector, value is shifting from patentable inventions toward AI models trained on large biobanks. The most insidious risk is "model laundering": Chinese companies train advanced algorithms on genomic data to which the West has no access. Even if the raw data never leaves China, the "weights" of the resulting model incorporate that value and can be exported, allowing for unfair competition in global markets.

This erosion is silent. Companies struggle to prove the misappropriation of knowledge that no longer fits within traditional intellectual property frameworks. Furthermore, the risk of “Bio-Cyber Espionage” involves Beijing using its own Biological Foundation Models to refine the intelligence of its systems by interacting with others’ proprietary databases without ever physically “stealing” a file. Companies must also address their exposure to vendors: cloud providers or CROs (Contract Research Organizations) that may have technical access exceeding contractual limits, leading to silent data leaks.

The Genomic Silk Road and the Dangers of Collaboration

To circumvent Western restrictions, China has launched the "Genomic Silk Road," establishing biobanks in the Middle East, Africa, and Southeast Asia. In this way, Beijing gains access to diverse genetic pools while imposing its own technical standards.

In Western countries, collaborations between their universities and China pose a risk that has now taken on a transnational dimension that is difficult to control. The concern is the transfer of "tacit knowledge": heuristics, workflows, and empirical judgments that researchers bring with them. The loss of a research team to Chinese universities with ties to the defense sector (talent mobility) can undo decades of investment faster than a hacker attack, since institutional knowledge about how to extract useful information from data is difficult to document and even harder to legally enforce.

Strategic Defense: Bio-Resilience and Cutting-Edge Technologies

The answer to this challenge is Bio-Resilience, which relies on the adoption of computing standards that protect data not only when it is stored, but also while it is being processed.

What Are Confidential Computing and TEEs?

In the context of life sciences, these technologies represent the only way to collaborate with foreign partners without “handing over the keys” to one’s information assets:

• Confidential Computing. This is a technology that isolates sensitive data in a secure portion of the processor during processing. Unlike traditional encryption (which protects data “at rest” or “in transit”), this protects data “in use.” This means that not even the system administrator or cloud provider can see what is being computed.

• Trusted Execution Environments (TEEs). These are secure hardware “enclaves.” Imagine a digital vault inside the chip. You can send your genomic data and the partner’s algorithm into the vault: the TEE performs the analysis, provides the result, but prevents the algorithm from copying the raw data and the user from seeing the algorithm’s logic.

Risk Matrix and Mitigation Strategies

1. Risks to Governments (National Security)

• Risk: Strategic Dependency. If China monopolizes bioproduction, the West loses the ability to respond autonomously to future pandemics or health crises.

• Risk: Transnational Bio-Surveillance. The use of exfiltrated genomic data to monitor citizens or dissidents, even abroad.

Mitigation: Implementation of “Sovereign Clouds” for health data, mandatory localization of critical data, and rigorous screening (Golden Power) of academic research agreements with entities linked to foreign governments.

2. Risks for Private Companies (Competitiveness)

• Risk: Loss of Intangible Assets. The theft of workflows and AI models (Model Laundering) that devalues existing patents.

• Risk: Vendor Exposure. Silent leaks through inadequately monitored cloud service providers or CROs.

Mitigation:

• Asset Segmentation. Identify “Crown Jewels” (core data) and isolate them in TEE environments.

• Contractual Governance. Include clauses for granular audits and rights to Early Injunctive Relief (preventive legal actions) based on data access telemetry.

• Traceability. Rigorously document every stage of the analysis workflow to be able to demonstrate, in court, the originality of your model against reverse-engineering attempts.

Operational Conclusion

Implementing these "secure partnerships," along with the segmentation of "Crown Jewels" and rigorous asset governance, is the only way to reconcile scientific progress with the protection of national security and private-sector competitiveness. The challenge for 2026 is no longer to close borders, but to build technological infrastructure where knowledge can be exchanged without being stolen.